Gene Expression Profiling of Triple-Negative Breast Tumors with Different Expression of Secreted Protein Acidic And Cysteine Rich (SPARC)

Abstract

To determine the expression signature of triple-negative breast cancer (TNBC) with differences of secreted protein acidic and rich in cysteine expression and clinical behavior. Patients, materials & methods: cDNA microarray analysis was performed to determine the expression profiling of TNBC, characterized regarding secreted protein acidic and rich in cysteine expression status. Immunohistochemistry analysis on tissue microarrays containing an independent cohort of TNBC was performed for validation. Results: Negative staining of SOHLH2 and positive staining of DNAJC12 and LIM1 was correlated with a poor outcome of the patients. Conclusion: Our findings provide new information on transcriptome changes associated with the clinical behavior of TNBC that may serve as a potential tool for the identification and characterization of new candidate biomarkers.

In silico analyses identify lncRNAs: WDFY3-AS2, BDNF-AS and AFAP1-AS1 as potential prognostic factors for patients with triple-negative breast tumors

“…In the present study, we sought to identify differentially expressed lncRNAs from a microarray data set available in the GEO database, generated in a previous study from our group [42]. The differentially expressed lncRNAs were further evaluated using different databases to assess their potential prognostic value for breast cancer patients.…”

“…A microarray data set, available on the Gene Expression Omnibus (GEO) online platform with access code GSE98931 [42] was reanalyzed by GeneSpring GX software (Agilent Technologies, Santa Clara, California, EUA) for identification of differentially expressed lncRNAs in SPARC positive vs. SPARC negative (fold change > = 1.5, p <0.05) after normalization and correction by Benjamini and Hochberg (Fig 1).…”

“…We found that low SPARC expression is associated with worse prognosis and more aggressive phenotypes of breast cancer, including TNBC [41]. More recently, we performed a study using cDNA microarrays to determine the expression profiling of a small subset of triple-negative breast tumors with differences in SPARC expression and clinical outcome, which lead us to identify several differentially expressed genes as potential new biomarkers candidate for TNBC [42].…”

“…In the present work, we sought to identify differentially expressed lncRNAs in TNBC with SPARC expression using a cDNA microarray data set obtained in a previous study from our group [42]. Using in silico analyses in combination with a review of the current literature, we examined the transcriptional profiles of lncRNAs between breast tumors and normal tissues and correlate gene expression levels to clinicopathological features and patient's clinical outcome.…”

Utilização de mineração de dados para avaliar perfis de expressão e potencial valor prognóstico de genes identificados em tumores de mama triplo negativo com expressão diferencial do SPARC (Secreted Protein Acidic Rich in Cisteine)

“…A principal limitação de tal estudo foi o número reduzido de pacientes TNBC provenientes de uma única instituição. Assim para testar futuras hipóteses validando genes diferencialmente expressos (identificados neste estudo) é necessário desenvolver estudos mais precisos com métodos de validação mais robustos usando coortes de grande escala(DE ALCANTARA FILHO et al, 2018). Adaptado de Mehanna e cols(2019) e Omarini e cols, (2018).…”